NCT05598775Enrolling by invitation
Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study
Source: ClinicalTrials.gov · Last updated 31 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this long-term safety study is to follow up subjects treated with CTX0E03 DP to monitor for delayed oncological, neurological, and CTX0E03 DP-related adverse events and to monitor survival
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 9 (estimated)
- First submitted
- 25 Oct 2022
- Start date
- 1 Nov 2022
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- ReNeuron Limited
- Diseases
- Stroke
- NCT number
- NCT05598775
What you commit to
- Study type: Observational
- Planned participants: 9
- From 1 Nov 2022 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Subjects who have received CTX0E03 DP as part of the active arm in the PISCES III study Have provided appropriate written informed consent
Age in the registry: 35 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amy Miller, RPh, PharmD Coordinator of this site? Confirm its status | Morgantown | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.